Secondary prevention after acute coronary syndrome

Česká verzia

Authors: Ján Murín ¹; Jozef Bulas ¹; Udovít Gašpar ^1,4; Alexander Klabník ²; Martin Wawruch ³
Authors place of work: I. interná klinika LF UK a UN Bratislava, Slovenská republika ¹; Kardiologická ambulancia, Oravská poliklinika, Námestovo, Slovenská republika ²; Ústav farmakológie a klinickej farmakológie LF UK Bratislava, Slovenská republika ³; Inštitút fyzioterapie, balneológie a liečebnej rehabilitácie Piešťany, Univerzita sv. Cyrila a Metoda v Trnave ⁴
Published in the journal: Vnitř Lék 2020; 66(4): 236-241
Category:

Summary

Patients suffering acute coronary syndrome have a very high risk for a repeated syndrome. After stabilization of acute coronary syndrome and discharge of a patient it is important to educate the patient how to prevent it in the future (dietary and life style changes), but treatment of all cardiovascular risk factors/diseases, as hypertension, dyslipidemia, diabetes but stabilization of all cardiovascular diseases is also important. Important is also antithrombotic treatment (mostly double antiplatelet treatment when percutaneous coronary intervention was used with a coronary stents), RAAS blockers, betablockers and statins (strong as atorvastatin and rosuvastatin in the highest possible dose). There are also new risk factors, and vascular inflammation belongs here. We have nowadays also some successful clinical studies how to block inflammation and how to use this treatment. A good secondary cardiovascular prevention is able to improve enourmously prognosis of these patients.

Keywords:

acute coronary syndrome – cardiovascular risk factors – secondary cardiovascular prevention – vascular inflammation

Zdroje

1. Fitzgerald DJ, Roy L, Catelia F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983–989.

2. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015; 65: 2211–2221.

3. Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. J Am Coll Cardiol 2016; 67: 2492–2502.

4. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133: e38–e48.

5. Kernis SJ, Harjai KJ, Stone GW, et al. The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1173–1177.

6. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104: 1229–1235.

7. Kornowski R, Goldbourt U, Zion M, et al. for the SPRINT Study Group. Predictors and long‑term prognostic significance of recurrent infarction in the year after a first myocardial infarction. Am J Cardiol 1993; 72: 883–888.

8. Trip MD, Cats VM, van Capelle FJL, et al. Platelet Hyperreactivity and Prognosis in Survi‑ vors of Myocardial infarction. N Engl J Med 1990; 322: 1549–1554.

9. Fox KAA, Carruthers KF, Dunbar DR, et al. Underestimated and under‑recognized: The late consequences of acute coronary syndrome (GRACE UK‑Belgian Study). Eur Heart J 2010; 31: 2755–2764.

10. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post‑myocardial infarction patients: Nationwide real world data demonstrate the importance of a long‑term perspective. Eur Heart J 2015; 36: 1136a–1170a.

11. Alnasser SMA, Huang W, Gore JM, et al. Late consequences of acute coronary syndromes: Global registry of acute coronary events (GRACE) follow‑up. Am J Med 2015; 128: 766–775.

12. Elgendy IY, Mahmoud AN, Kumbhani DJ, et al. Complete or culprit‑only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta‑analysis of randomized trials. J Am Coll Cardiol Intv 2017; 10: 315–324.

13. Smits PC, Abdel‑Wahab M, Neumann FJ et al. Fractional flow reserve‑guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017; 376: 1234–1244.

14. Engstrøm T, Kelbaek H, Helqvist S et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST‑segment elevation myocardial infarction and multivessel disease (DANAMI 3-PRIMULTI): an open‑label randomised controlled trial. Lancet (London, England) 2015; 386: 665–671.

15. Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion‑only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease. The CvLPRIT trial. J Am Coll Cardiol 2015; 65: 963–972.

16. Farooq V, Serruys PW, Bourantas CV, et al. Quantification of incomplete revascularization and its association with five‑year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013; 128: 141–151.

17. Généreux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: The residual SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol 2012; 59: 2165–2174.

18. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part II. Circulation 2003; 108: 1772–1778.

19. Arbab‑Zadeh A, Fuster V. The myth of the „vulnerable plaque“: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Col Cardiol 2015; 65: 846–855.

20. Chow CK, Jolly S, Rao‑Melacini P et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circu‑ lation 2010; 121: 750–758.

21. Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL‑lowering therapy among men and women: Meta‑analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015; 385: 1397–1405.

22. Antithrombotic Trialists’ Collaboration. Collaborative meta‑analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.

23. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016; 37: 1720–1722.

24. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

25. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

26. Murín J, Čaprnda M, Kasperová V. Čo priniesla klinická štúdia ODYSSEY OUTCOMES. Cardiol Lett 2018; 27: 62–67.

26a. Sabatine MS, Giugliano RP, Keech AC, et al (FOURIER). Evolocumab and clinical outcomes in patients with cardiovascular disease. N Emgl J Med 2017; 376: 1713–1722.

27. Bonaca MP, Bhatt DL, Cohen M, et al. Long‑term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791–1800.

28. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.

29. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation. Eur Heart J 2016; 37: 267–315.

30. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST‑segment elevation. Eur Heart J 2018; 39: 119–177.

31. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Hear J 2018, 39: 213–254.

32. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

33. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.

34. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68: 1082–1115.

35. Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13–C18.

36. Kubo T, Maehara A, Mintz GS, et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Col Cardiol 2010; 55: 1590–1597.

37. Rioful G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three‑vessel intravascular ultrasound study. Circulation 2002; 106: 804-808.

38. Mann J, Davies MJ. Mechanism of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82: 265–268.

39. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934–940.

40. Ain DL, Jang IK. Natural history of coronary atherosclerosis. Coron Artery Dis 2015; 26: 463–465.

41. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‑segment elevation. N Engl J Med 2001; 345: 494–502.

42. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–2420.

43. Collet JP, Silvain J, Barthélémy O, et al. Dual‑antiplatelet treatment beyond 1 year after drug‑eluting stent implanation (ARTIC‑interruption): a randomised trial. Lancet 2014; 384: 1577–1585.

44. Lemesle G, Tricot O, Meurice T, et al. Incident myocardial infarction and very late stent thrombosis in outpatients with stable coronary artery disease. J Am Coll Cardiol 2017; 69: 2149–2156.

45. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double‑blind, placebo‑controlled trial. Lancet 2017; 6736: 1–14.

46. Tangri N, Ferguson TW, Whitlock RH, et al. Long term health outcomes in patients with a history of myocardial infarction: a population based cohort study. PloS One 2017; 12: 1–11.

47. Kern DM, Mellström C, Hunt PR, et al. Long‑term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population. Curr Med Res Opin 2016; 32: 703–711.

48. Schömig A, Neumann F‑J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary‑artery stents. N Engl J Med 1996; 334: 1084–1089.

49. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic‑drug regimens after coronary‑artery stenting. N Engl J Med 1998; 339: 1665–1671.

49a. Wallentin L, Becker RC, Budaj A, et al. (PLATO study) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.

50. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural‑history study of corona‑ ry atherosclerosis. N Engl J Med 2011; 364: 226–235.